UK markets open in 37 minutes

NVO Jan 2025 75.000 put

OPR - OPR Delayed price. Currency in USD
Add to watchlist
0.25000.0000 (0.00%)
As of 03:37PM EDT. Market open.
Full screen
Previous close0.2500
Open0.2500
Bid0.1100
Ask0.3900
Strike75.00
Expiry date2025-01-17
Day's range0.2500 - 0.2500
Contract rangeN/A
Volume1
Open interest208
  • Zacks

    Novo Nordisk (NVO) Advances While Market Declines: Some Information for Investors

    In the most recent trading session, Novo Nordisk (NVO) closed at $133.28, indicating a +0.08% shift from the previous trading day.

  • Benzinga

    Britain's Drug Regulator Approves Novo Nordisk's Weight Loss Drug Wegovy To Cut Heart Disease Risk In Obese Patients

    On Tuesday, the U.K.’s Medicines and Healthcare products Regulatory Agency (MHRA) approved a new indication for Novo Nordisk A/S’s (NYSE:NVO) semaglutide (Wegovy) to reduce the risk of overweight and obese adults suffering heart problems or strokes. This medicine, a GLP-1 receptor agonist, was already approved for use in the treatment of obesity and weight management, alongside diet, physical activity, and behavioral support. Also Read Oral Weight Loss Drugs Vs. Injections – Pills Are Promising

  • Bloomberg

    Ozempic Maker Novo Tees Up Another Major Building Project

    (Bloomberg) -- Novo Nordisk A/S has secured land and planning permissions for what may be its next major factory site in Denmark as the 100-year-old company works to meet soaring demand for its weight loss drugs. Most Read from BloombergHarris Has Enough Delegates to Clinch Nomination for PresidentTrump Risks Getting Tables Turned on Him With New 2024 AdversaryWiz Rejects Google’s $23 Billion Offer, Seeks IPO InsteadA Six-Second Decision Shows How Harris Snapped Up DelegatesHarris Wins Soros Bac